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Abstract
The purpose of this study was to evaluate
DNA damage in the whole genome of
peripheral blood leukocytes from patients
with acute myeloid leukemia (AML) com-
pared with a control group using DNA
breakage detection-fluorescent in situ
hybridization (DBD-FISH). Our results
suggest that the DNA damage detected in
patients with newly diagnosed AML was
similar to that observed for the controls; this
might be explained by the stimulation of a
repair pathway by the pathogenesis itself.
These findings indicate that inhibiting the
repair pathway could be proposed to
enhance the efficacy of chemotherapy.
Introduction
Acute myeloid leukemia (AML) is a very
heterogeneous disorder in which hemopoi-
etic progenitor cells (blasts) lose their abili-
ty to differentiate normally and respond to
normal regulators of proliferation. AML is
the most common form of acute leukemia in
adults, with a median age at diagnosis of
65-70 years.1 The prognosis of patients with
AML is poor. In patients younger than 60
years, the complete remission (CR) rate is
60-70%, whereas the overall cure rate is
only 35-40%.2,3 Elderly patients and those
with adverse karyotypes exhibit a CR rate
of 35-50% and a cure rate of 10% or less.2
This pathology is associated with genomic
damage characterized by a variety of chro-
mosomal and molecular changes,4 which
can be useful for associations with patho-
genesis, progression, and chemotherapy
response or resistance.5 The few studies that
assessed genomic damage in patients with
leukemia used approaches such as the
micronucleus (MN) technique,6,7 sister
chromatid exchange (SCE),8-12 or the alka-
line comet assay.13,14 The findings of those
studies were contradictory. DNA damage in
Mexican patients with AML has not been
explored. Currently, the DNA breakage
detection-fluorescent in situ hybridization
(DBD-FISH) technique ex vivo that allows
the quantification of single-stranded DNA
breaks (SSBs) and alkali-labile sites in the
whole genome or specific sequences.15
The purpose of this preliminary study
was to evaluate DNA damage in the whole
genome of peripheral blood leukocytes
(PBL) from Mexican patients with newly




We enrolled patients with AML from the
Unidad Medica de Alta Especialidad No. 25
(UMAE 25), Instituto Mexicano del Seguro
Social (IMSS). The clinical diagnosis was
based on the morphological characteristics
of Wright-Giemsa-stained smears of bone
marrow aspirates and on immune-pheno-
typing analyses of leukemic cells.
Hematological data of peripheral blood
reveled that all patients registered high per-
centage of leukemia blasts (67-96%).
Controls showed only normal leucocytes.
The study participants were classified as
newly diagnosed patients [n=22; age (aver-
age ±SD) = 41±18.87 years (range 17-65
years)] and healthy volunteers, who served
as controls [n=13; age 37±14.38 years
(range 19-64 years)].
Written informed consent was obtained
from all patients. The protocol was
approved by the Research and Ethics
Committee of IMSS (R-2015-785-033).
DBD-FISH technique
DBD-FISH was performed in PBL sam-
ples from patients and controls. The pro-
tein-depletion procedure followed by treat-
ment with an alkaline solution to produce
SSBs was performed according to
Fernández and Gosálvez.15
To determine the total DNA damage, a
whole-genome DNA probe was produced
from leukocyte pellets by using a DNA iso-
lation kit for mammalian blood (Roche
Diagnostics Co., Indianapolis, IN, USA).
The hybridized DNA probe was detected by
incubation for 30 min with fluorescein
isothiocyanate-labeled avidin (1:400;
Roche Diagnostics Co.). Finally, the slides
were counterstained with 4’,6-diamidino-2-
phenylindole (DAPI) (1 mg/mL) in
Vectashield mounting medium (Vector
Laboratories, Burlingame, CA, USA). 
Comet assay
To confirm the results obtained with
DBD-FISH, the alkaline comet assay was
performed using the basic rationale of
Singh et al.,16 with modifications.17 The
quantification of DNA damage was per-
formed by protein-depletion, treatment with
an alkaline solution and SSBs migration in
an electric field. 
Treatment with H2O2 (positive control)
Each experiment included two positive
controls; a sample of healthy volunteers and
one of AML patient. Slides were exposed to
H2O2 (20 mM), previously to DBD-FISH
technique. 
Repair experiment in vitro
PBL from a 37-year-old female who was
newly diagnosed with AML were used to
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perform three cultures on RPMI-1640
medium supplemented with fetal calf serum
(Gibco-Life Technologies, Waltham, MA,
USA):  to evaluate DNA damage, cells were
treated with mitomycin C (0.2 mg/mL) for
48 h; to evaluate DNA repair, cells were
treated with mitomycin C for 72 h; and cells
was used as the negative control because it
was not treated with any mutagenic agent.
All cultures were harvested at 72 h for pro-
cessing through the DBD-FISH technique. 
The same strategy was applied to a sam-
ple of control PBL from an age- and sex-
matched healthy individual. Two replicates
for each experiment were performed.
Image analysis
The slides were analyzed using a digital
image analysis platform based on a Zeiss
Axiophot fluorescence microscope (Carl
Zeiss, Göttingen, Germany). The Images were
recorded using an Axiocam 16-bit black-and-
white charge-coupled device in a 12-bit TIFF
format. The integrated density (ID) values
obtained after background subtraction were
calculated using Image J 1.4.3.6.7.
(http://rsb.info.nih.gov/ij/). For this purpose,
ID (area x gray scale) after background sub-
traction was calculated in pixels (px).18 Fifty
cells were analyzed for each sample.
Statistical analysis
Data were entered a database for statisti-
cal analysis. All analyses were performed
using the package IBM-SPSS for Windows
20.0 (IBM Corp., Armonk, NY, USA). The
ID in the four groups studied was trans-
formed using log10. The mean values for
transformed data and for not transformed
data were analyzed by one-way ANOVA. A
P-value less than 0.05 was considered sig-
nificant.  The sample size was estimated
using the Minitab software (ver. 15) for
one-way ANOVA (α = 0.05, 1 - β = 0.80,
corrected sum of the squares of means =
2534102586, and Sigma = 54400.5). A min-
imum sample size of 13 individual per
group was obtained. Significance was set at
P<0.05 for all tests.
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Table 1. Integrated density values in peripheral blood leukocytes of acute myeloid
leukemia patients after DBD-FISH using probe whole genome.
                                               Fluorescence analysis 
Group                                    n             ID (average ±SE*)a                  ID (average ±SE*)b
Healthy (A)                                      13                          18.99±4.393,4                                             4.17±0.933,4
AML (B)                                            22                          17.34±3.833,4                                             4.08±0.093,4
Positive control-healthy (C)        13                         79.37±24.971,2                                            4.63±0.141,2
Positive control-AML (D)             22                        126.71±28.491,2                                           4.71±0.161,2
ID, integrated density; *average ±SE values represent 103; anot transformed ID values; btransformed ID values; AML, acute myeloid
leukemia; Test ANOVA: 1different from group A, P<0.05; 2different from group B, P<0.05; 3different from group C, P<0.05; 4different
from group D, P<0.05.
Table 2. Experiments for evaluate DNA damage/reparation by DBD-FISH in peripheral blood leukocytes cultures of a patients with
acute myeloid leukemia and a healthy individual after exposition at mitomycin-C. 
                                 Acute myeloid leukemia sample                                                                           Healthy sample
Time          Control                       Damage                   Reparation                                  Control                 Damage                       Reparation
T0                                                                                                                    MMC                                                                                                                                                MMC
24 h                                                                   MMC                                                                                                                                           MMC                                              
72 h                  Harvest                                Harvest                                Harvest                                                 Harvest                         Harvest                                    Harvest
ID                       18.39                                    287.13                                   60.05                                                      16.48                             123.80                                        30.80 
Time, time of culture; damage, culture with exposition to mitomycin-C for 48 h for evaluating DNA damage; reparation, culture with exposition to mitomycin-C for 72 h for evaluating DNA damage; control,
represent DNA damage and reparation levels in a culture without the exposition mutagenic agent; ID, integrated density average value in pixels; MMC, mitomycin-C.
Figure 1. Analysis of DNA damage in peripheral blood leukocytes after DBD-FISH using
whole probe labeled with biotin (red) and counterstained with DAPI (blue). A) Healthy
individual; B) patient with AML; C) positive control healthy (H2O2). Analysis by comet
assay (Comet tail µm): A’) 42.7±6.1; B’) 47.4±8.3; C’) 130±11.8. Scale bars: A-C) 5 µm;
A’-C’) 10 µm.
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Results
The average age was similar among the
groups (P>0.05). Cells that were treated
with hydrogen peroxide exhibited elevated
ID values, which confirmed the accessibili-
ty of the cells to the tested chemicals
(Figure 1C). Conversely, cells without treat-
ment showed a slight fluorescent signal that
corresponded to the basal or constitutive dam-
age for this type of cells (Figure 1A). Patients
with AML demonstrated similar results to the
negative control group (Figure 1). The results
presented above were confirmed by the
comet assay (Figure 1A’-C’).
The analysis of the ID in the group of
patients with AML (Figure 1B) yielded
results that were similar (P>0.05) to those
obtained for the control group (Figure 1A).
Leukocytes of positive controls (treated
with H2O2) of healthy and AML, showed a
significant increase in ID compared with
the group of AML patients and healthy
group (P<0.05) (Table 1).
The repair experiment performed on
leukocytes from a patient with AML
showed an ID value that suggest a sensitiv-
ity higher to damage (287.13 px) than con-
trol cells (123.8 px) and repair efficiency
similar in the two groups of cells (21% and
24%, respectively). Finally, ID values of
AML and healthy control were similar
(Table 2).
Discussion
Our results demonstrated that the DNA
damage detected in patients with newly
diagnosed AML was similar to that
observed for the controls. Previous studies
of DNA damage in patients with newly
diagnosed leukemia vs controls used in vitro
techniques, such as SCE8-10,19 and the MN6,7
tests showed findings contradictory. To our
knowledge, only a study of DNA damage ex
vivo in PBL of patients with newly diag-
nosed leukemia vs controls used the alka-
line comet assay to determinate DNA dam-
age in patients with AML from Cairo,
Egypt, showed that the tail moment was sig-
nificantly higher in patients compared with
the control group.13 This result disagrees
with our findings from Mexican patients,
ethnic differences could be one of the
causes underlie this discrepancy.20,21
Our results may be attributed to repair-
induced DNA lesions. This capacity to
repair was reported previously by Müller et
al.22 for lymphocytes from patients with
Chronic lymphocytic leukemia who were
nonresponsive to alkylating agents. Those
cells exhibited faster processing repair-
induced SSBs compared with control cells,
which could be explained by the presence
of cytotoxic DNA lesions induced by the
alkylating agents. Recently, Portich et al.14
assessed DNA damage in pediatric patients
with acute lymphoid leukemia using the
comet assay and found no increase in dam-
age during induction therapy (diagnosis, 15
days, and 35 days), which suggests that this
repair pathway may be stimulated in the fol-
lowing scenarios: i) as a tumor response; ii)
as a defense from chemotherapy; or iii) both
(pathogenesis of the disease and chemother-
apy).
Our findings support the first scenario
because we did not find increased damage
in patients with newly diagnosed AML
compared with the control group. In addi-
tion, the repair experiment performed on
leukocytes from a patient with AML are
indicative that the sensitivity to damage in
cells from the patients was greater that of
the control cells, and the percentage of
repair was similar in the two groups.
To confirm our findings, it will be neces-
sary to perform studies using DBD-FISH
with probes for specific chromosomal
regions8,23 with significance in leukemogen-
esis or for genes involved in DNA damage
and repair, which have been identified in
AML patients.5,13,24-26 This information may
be useful for the measurement of cellular
interindividual heterogeneity3 and to per-
form associations with sensitivity to the
pathology itself or to chemotherapy.24,26
In conclusion, in this study preliminary
we reported absence of an increase in DNA
damage in patients with newly diagnosed
AML compared with controls and suggest-
ed that this may be explained by the stimu-
lation of a repair pathway by the pathogene-
sis itself. Future studies are needed to con-
firm our findings
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